These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 14654556

  • 1. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
    Papadopoulou MV, Bloomer WD.
    Clin Cancer Res; 2003 Nov 15; 9(15):5714-20. PubMed ID: 14654556
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec 15; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
    Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.
    Radiat Res; 2007 Jul 15; 168(1):65-71. PubMed ID: 17722994
    [Abstract] [Full Text] [Related]

  • 12. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002 Jul 15; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 13. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006 Jul 15; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
    Papadopoulou MV, Rosenzweig HS, Bloomer WD.
    Bioorg Med Chem Lett; 2004 Mar 22; 14(6):1523-5. PubMed ID: 15006395
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257).
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2003 Mar 22; 14(1):21-9. PubMed ID: 14552588
    [Abstract] [Full Text] [Related]

  • 18. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV, Pouremad R, Rao MK, Ji M, Bloomer WD.
    In Vivo; 2001 Mar 22; 15(5):365-71. PubMed ID: 11695231
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1999 Mar 22; 11(8):345-57. PubMed ID: 10803738
    [Abstract] [Full Text] [Related]

  • 20. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV, Ji M, Bloomer WD.
    Cancer Chemother Pharmacol; 2001 Aug 22; 48(2):160-8. PubMed ID: 11561782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.